We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Erasca Inc | NASDAQ:ERAS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 5.41% | 1.95 | 1.90 | 1.96 | 53,723 | 13:45:47 |
From May 2023 to May 2024
By Sabela Ojea
Erasca said Thursday that its Eras-801 medication aimed at treating brain tumors was granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Shares rise 3.4% to $2.75 in after-hours trading.
The clinical-stage oncology company said Eras-801 has been designated to treat aggressive brain tumors such as Glioblastoma.
While orphan-drug status doesn't guarantee FDA approval as a treatment for a rare disease, it is a prerequisite for getting incentives such as tax breaks and marketing exclusivity if the agency approves the drug for that purpose.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 22, 2023 16:41 ET (20:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Erasca Chart |
1 Month Erasca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
